Non-small Cell Lung Cancer (NSCLC) Clinical Trials
7 recruiting trials for Non-small Cell Lung Cancer (NSCLC). Eligibility criteria explained in plain English.
TrialFinderData lists 7 Non-small Cell Lung Cancer (NSCLC) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 1 is the largest group at 57% (4 studies); the largest phase groups are Phase 1: 4, Phase 1 / Phase 2: 3.
Research is led by Novartis Pharmaceuticals (1), National Cancer Institute (NCI) (1), Olivera Finn (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is paclitaxel (drug, 2 trials), followed by 68Ga-DFC413, 68Ga-NNS309.
Track Non-small Cell Lung Cancer (NSCLC) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
The purpose of Part 1 of this study is to evaluate the imaging characteristics, safety, biodistribution and pharmacokinetics of \[68Ga\]Ga-DFC413, and in Part 2 compare to...
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined...
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Surgery to remove the...
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
All subjects will receive the vaccine subcutaneously every 3 weeks x 3 with optional yearly booster vaccines up to and including 5 years post last vaccine for those patients who...
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in...
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in...
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...
Explore Other Conditions
Frequently Asked Questions
There are currently 7 clinical trials for Non-small Cell Lung Cancer (NSCLC), with 7 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Non-small Cell Lung Cancer (NSCLC), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Non-small Cell Lung Cancer (NSCLC), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.